P104 Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet's disease
D.H. Kim*1, 2, B. Kim1, S.J. Park1, S.P. Hong1, T.I. Kim1, W.H. Kim1, J.H. Cheon1
1Institute of Gastroenterology, Yonsei University College of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 2CHA University, Gastroenterology, Seongnam, Korea, Republic of
Little is known about the usefulness of fecal calprotectin (FC) measurement in predicting intestinal involvement of Behçet's disease (BD).
Forty four consecutive patients with systemic BD who underwent colonoscopy for the evaluation of gastrointestinal symptoms were prospectively enrolled between November, 2012 and March, 2014 in a single tertiary medical center. Fecal specimens from the patients were obtained the day before bowel cleansing.
Twenty five patients showed intestinal ulcerations on colonoscopy [12 (48.0%) typical and 13 (48.0%) atypical ulcerations]. Of them, six (24.0%) definite, eighteen (72.0%) probable, and one (4.0%) suspected intestinal BD were diagnosed according to the validated criteria for intestinal BD. Mean FC level of intestinal BD group was significantly higher than of non-diagnostic group (306.5 ± 367.7 vs. 59.9 ± 85.4, respectively, P=0.012). Moreover, typical ulceration group showed significantly higher FC level than atypical ulceration group in patients with intestinal BD (476.3 ± 444.5 vs. 149.7 ± 183.8, respectively, P=0.033). Multivariate analysis revealed higher FC as an independent predictor of intestinal BD (OR=1.014; 95% CI = 1.000-1.028; P=0.043). The cut-off levels of FC were 110.44 μ g/g (83.3% sensitivity and 81.2% specificity) for predicting typical ulceration and 68.89 μ g/g (75.0% sensitivity and 75.5% specificity) for predicting intestinal BD.
FC level might have a significant role as a non-invasive surrogate marker of intestinal involvement of BD.